PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 15683947

[DHEA and aging].

Hélène Pitti-Ferrandi
View original source ↗Export metadata ↓

Abstract

DHEA and its ester sulfate metabolite, DHEAS, are steroids mainly secreted by the adrenal cortex, but also within the brain where they are considered as neurosteroids. No receptor was identified for DHEA or DHEAS. Their putative effects are mediated by their conversion into active sexual streroids, estradiol and testosterone, but their role is not clarified. Decreased serum levels of DHEA\DHEAS are associated with aging and have also been found in age-associated diseases. However, the results of epidemiological studies are contradictory and few therapeutic trials were published. A positive effect was found on the libido, bone status and skin in women over 70 years of age. No clear effect was evidenced on the cognitive status. Some studies showed a beneficial effect on thymic disorders, but this effect remains to be confirmed. We don't know the possible negative consequences of long-term administration of DHEA\DHEAS on cardiovascular disease and hormone-dependent cancers. Therefore, DHEA administration should not be recommended for aged people.

Explore related subjects

Adjuvants, ImmunologicAgedAgingAlzheimer DiseaseCognition DisordersDehydroepiandrosteroneEpidemiologic StudiesFemaleHumansLibidoMaleMiddle AgedEnglish AbstractJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Hélène Pitti-Ferrandi. 2003. [DHEA and aging].. https://pubmed.ncbi.nlm.nih.gov/15683947/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Immunostimulatory RNA oligonucleotides trigger an antigen-specific cytotoxic T-cell and IgG2a response.

Single-stranded RNA oligonucleotides containing an immunostimulatory motif (immunostimulatory RNA [isRNA]) are potent inducers of interferon-alpha via the Toll-like receptor 7. We investigated the effect of isRNA on the development of an immune response. We show that isRNA activates dendritic cells and induces production of Th1-type cytokines both in vitro and in vivo. Cytokine production led to bystander activation of T and B cells. We further demonstrate that isRNA triggers the generation of antigen-specific cytotoxic T cells and of an IgG2a-biased antibody response to antigen in a sequence-dependent manner. In summary, we provide evidence for the first time that isRNA oligonucleotides can simultaneously activate the innate and adaptive arms of the immune system.

Adjuvants, Immunologic↗
PubMed2007

Lactobacillus delbrueckii as a potential skin adjuvant for induction of type 1 immune responses.

We evaluated the ability of Lactobacillus delbrueckii UFV H2b20, a probiotic candidate, to stimulate the production of inflammatory cytokines and to induce macrophage activation and Th1 differentiation in peripheral blood mononuclear cells (PBMC) from healthy volunteers. Our results show that PBMC stimulated with heat-killed Lact. delbrueckii produced elevated levels of IL-12, IFN-gamma and TNF-alpha but no IL-10. IFN-gamma production was IL-12 dependent with NK cells as the main source. Furthermore, PBMC infected with Leishmania amazonensis presented elevated microbicidal activity when co-incubated with Lact. delbrueckii. Finally, Lact. delbrueckii was capable of inducing in vitro differentiation of L. amazonensis-specific Th1 cells. These findings suggest that this probiotic may be used as an adjuvant in vaccination protocols.

Adjuvants, Immunologic↗
PubMed2007

Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites.

Brother of the regulator of imprinted sites (BORIS) was previously described as a transcription factor for epigenetic reprogramming the expression of which is strictly confined to germ cells of adult testes but is aberrantly activated in the vast majority of neoplastic cells. Considering the critical role of BORIS in cancerogenesis and the fact that its expression pattern may preclude thymic tolerance, we generated DNA- and protein-based mouse BORIS antitumor vaccines using a non-DNA-binding version of the BORIS molecule. Clinical use of BORIS as a vaccine Ag would require that certain safety concerns be met. Specifically, administration of the functional BORIS protein would hypothetically pose a risk of BORIS accelerating the progression of cancer. To alleviate such safety concerns, we have developed vaccines based on the BORIS molecule lacking the DNA-binding zinc fingers domain. To enhance anti-BORIS cellular immune responses, we used a standard molecular adjuvant approach. It consisted of plasmids encoding murine IL-12 and IL-18 for a DNA-based vaccine and conventional Th1 type adjuvant, Quil A, for a protein-based vaccine. Both DNA- and protein-based vaccines induced Ag-specific CD4(+) T cell proliferation with Th1 and Th2 cytokine profiles, respectively. Protein-based, but not DNA-based, BORIS vaccine induced a significant level of Ab production in immunized animals. Importantly, potent anticancer CD8(+)-cytotoxic lymphocytes were generated after immunization with the DNA-based, but not protein-based, BORIS vaccine. These cytolytic responses were observed across a wide range of different mouse cancers including mammary adenocarcinoma, glioma, leukemia, and mastocytoma.

Adjuvants, Immunologic↗